ライフサイエンスコーパス: veno-occlusive

1 ty, any infection, organ failure, or hepatic veno-occlusive disease (1-year cumulative incidence, 71%

2 PTCY had significantly higher rates of veno-occlusive disease (14.4% vs TCRalphabeta 4.9%, P =

3 Hepatic veno-occlusive disease (HVOD), alias sinusoidal obstruct

4 sed as a common mechanism leading to hepatic veno-occlusive disease (HVOD).

5 8-5.5), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6).

6 Low L-Ficolin was associated with hepatic veno-occlusive disease (P = .0053, AUC = 0.80).

7 Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonar

8 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

9 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

10 ry arterial hypertension (PAH) and pulmonary veno-occlusive disease (PVOD), respectively.

11 lungs, and it is therefore termed pulmonary veno-occlusive disease (PVOD).

12 s (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17).

13 en successfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (M

14 Rates of veno-occlusive disease (VOD) and thrombotic microangiopa

15 bstruction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem

16 We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and re

17 Hepatic veno-occlusive disease (VOD) is a common complication of

18 Hepatic veno-occlusive disease (VOD) is one of the most serious

19 Hepatic veno-occlusive disease (VOD) is the most common of the r

20 Veno-occlusive disease (VOD) is the most common regimen-

21 Hepatic veno-occlusive disease (VOD) is the most serious regimen

22 Veno-occlusive disease (VOD) is the third leading cause

23 One patient treated at 9 mg/m2 developed veno-occlusive disease (VOD) of the liver and defined th

24 The incidence of hepatic veno-occlusive disease (VOD) was 5% for IV-BU and 1% wit

25 Hepatic veno-occlusive disease (VOD), also called sinusoidal obs

26 ibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement

27 mg/m(2) per day after recognition of hepatic veno-occlusive disease (VOD).

28 had dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

29 One patient developed nonfatal veno-occlusive disease after induction II.

30 Rates of veno-occlusive disease and interstitial pneumonitis were

31 in two ultra-rare subtypes of PAH, pulmonary veno-occlusive disease and pulmonary capillary haemangio

32 tioned well initially, the patient developed veno-occlusive disease and required repeat transplantati

33 irected deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectab

34 sease, organ failure, infections, or hepatic veno-occlusive disease between groups.

35 As soon as a veno-occlusive disease diagnosis is established, treatme

36 ry by etiology, with patients with pulmonary veno-occlusive disease displaying a lack of microvascula

37 ary hypertension and differentiate pulmonary veno-occlusive disease from pulmonary arterial hypertens

38 was also a trend toward an increased risk of veno-occlusive disease in patients with high ferritin.

39 Pulmonary veno-occlusive disease is caused by excessive cell proli

40 Variation in clinical practice affects veno-occlusive disease management, mainly in patients wh

41 Veno-occlusive disease may also affect the lungs, and it

42 Veno-occlusive disease occurred twice with cyclophospham

43 No additional cases of veno-occlusive disease occurred.

44 Severe veno-occlusive disease of the liver occurred in 9 (21%)

45 Additionally, 95 patients developed veno-occlusive disease of the liver.

46 ificant acute graft-versus-host disease, and veno-occlusive disease of the liver.

47 the initiation of pulmonary vasodilators in veno-occlusive disease often leads to increased mortalit

48 otaline administration led to severe hepatic veno-occlusive disease on day 6.

49 lantation-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host diseas

50 Treosulfan causes less veno-occlusive disease than busulfan and does not requir

51 ary ERG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation w

52 n and melphalan group had Bearman grades 1-3 veno-occlusive disease versus 21 (9%) of 239 in the carb

53 The incidence of veno-occlusive disease was 40% (13 of 32 patients) in pl

54 The day 100 incidence of veno-occlusive disease was lower with Flu/Mel (4%) and F

55 ft failure with Flu/Mel and the high rate of veno-occlusive disease with Bu/Cy and Flu/Bu, Flu/Mel/TT

56 l recessive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (V

57 ple sclerosis, chronic lymphocytic leukemia, veno-occlusive disease with immunodeficiency, as well as

58 elopment of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin lev

59 ction (presenting as the syndrome of hepatic veno-occlusive disease) are all associated with signific

60 nusoidal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatme

61 d $20,500, respectively), whereas infection, veno-occlusive disease, acute graft-versus-host disease,

62 nary capillary hemangiomatosis and pulmonary veno-occlusive disease, an autosomal recessively inherit

63 and 3 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancyt

64 obstructive syndrome, also known as hepatic veno-occlusive disease, is a potentially life-threatenin

65 nusoidal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatenin

66 H, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to c

67 vely evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-ve

68 17 patients (3%) had hepatic veno-occlusive disease.

69 is crucial for the development of pulmonary veno-occlusive disease.

70 transaminase and bilirubin without signs of veno-occlusive disease.

71 dysfunction, and a high frequency of hepatic veno-occlusive disease.

72 eveloped severe hepatotoxicity suggestive of veno-occlusive disease.

73 Two patients had reversible hepatic veno-occlusive disease.

74 used as therapy for Budd-Chiari syndrome and veno-occlusive disease.

75 or of 100-day mortality was the diagnosis of veno-occlusive disease.

76 acteristic that predicted the development of veno-occlusive disease.

77 al toxicities, with typical mucositis and no veno-occlusive disease.

78 4 gene (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

79 opathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

80 athic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

81 ients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

82 Classical veno-occlusive disease/sinusoidal obstruction syndrome (

83 imiting toxicities were observed (reversible veno-occlusive disease; 0.180 mg/kg, n=1 and 0.450 mg/kg

84 erapy; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant gr

85 Mesenteric inflammatory veno-occlusive disorder (MIVOD) is a rare variety of inf

86 Veno-occlusive liver disease of any grade occurred in 15

87 Veno-occlusive liver disease was a major adverse event a

88 zed into three types: ischaemic (low-flow or veno-occlusive), non-ischaemic (high-flow or arterial) a